Melanie Leveridge on ELRIG and a career in drug discovery

Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton abo...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Melanie Leveridge [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Übergeordnetes Werk:	In: Future Drug Discovery - Future Science Ltd, 2021, 3(2021), 1
Übergeordnetes Werk:	volume:3 ; year:2021 ; number:1

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.4155/fdd-2020-0030

Katalog-ID:	DOAJ010637346

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ010637346
003	DE-627
005	20230502072117.0
007	cr uuu---uuuuu
008	230225s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.4155/fdd-2020-0030 \|2 doi
035			\|a (DE-627)DOAJ010637346
035			\|a (DE-599)DOAJ9835a389e95741e3beb1953ecb05312e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RS1-441
100	0		\|a Melanie Leveridge \|e verfasserin \|4 aut
245	1	0	\|a Melanie Leveridge on ELRIG and a career in drug discovery
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery.
653		0	\|a Pharmacy and materia medica
773	0	8	\|i In \|t Future Drug Discovery \|d Future Science Ltd, 2021 \|g 3(2021), 1 \|w (DE-627)1760793973 \|x 26313316 \|7 nnns
773	1	8	\|g volume:3 \|g year:2021 \|g number:1
856	4	0	\|u https://doi.org/10.4155/fdd-2020-0030 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/9835a389e95741e3beb1953ecb05312e \|z kostenfrei
856	4	0	\|u https://www.future-science.com/doi/10.4155/fdd-2020-0030 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2631-3316 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 3 \|j 2021 \|e 1

Indexfelder

author_variant	m l ml
matchkey_str	article:26313316:2021----::eailvrdenliadcreid
hierarchy_sort_str	2021
callnumber-subject-code	RS
publishDate	2021
allfields	10.4155/fdd-2020-0030 doi (DE-627)DOAJ010637346 (DE-599)DOAJ9835a389e95741e3beb1953ecb05312e DE-627 ger DE-627 rakwb eng RS1-441 Melanie Leveridge verfasserin aut Melanie Leveridge on ELRIG and a career in drug discovery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery. Pharmacy and materia medica In Future Drug Discovery Future Science Ltd, 2021 3(2021), 1 (DE-627)1760793973 26313316 nnns volume:3 year:2021 number:1 https://doi.org/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/article/9835a389e95741e3beb1953ecb05312e kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2021 1
spelling	10.4155/fdd-2020-0030 doi (DE-627)DOAJ010637346 (DE-599)DOAJ9835a389e95741e3beb1953ecb05312e DE-627 ger DE-627 rakwb eng RS1-441 Melanie Leveridge verfasserin aut Melanie Leveridge on ELRIG and a career in drug discovery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery. Pharmacy and materia medica In Future Drug Discovery Future Science Ltd, 2021 3(2021), 1 (DE-627)1760793973 26313316 nnns volume:3 year:2021 number:1 https://doi.org/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/article/9835a389e95741e3beb1953ecb05312e kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2021 1
allfields_unstemmed	10.4155/fdd-2020-0030 doi (DE-627)DOAJ010637346 (DE-599)DOAJ9835a389e95741e3beb1953ecb05312e DE-627 ger DE-627 rakwb eng RS1-441 Melanie Leveridge verfasserin aut Melanie Leveridge on ELRIG and a career in drug discovery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery. Pharmacy and materia medica In Future Drug Discovery Future Science Ltd, 2021 3(2021), 1 (DE-627)1760793973 26313316 nnns volume:3 year:2021 number:1 https://doi.org/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/article/9835a389e95741e3beb1953ecb05312e kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2021 1
allfieldsGer	10.4155/fdd-2020-0030 doi (DE-627)DOAJ010637346 (DE-599)DOAJ9835a389e95741e3beb1953ecb05312e DE-627 ger DE-627 rakwb eng RS1-441 Melanie Leveridge verfasserin aut Melanie Leveridge on ELRIG and a career in drug discovery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery. Pharmacy and materia medica In Future Drug Discovery Future Science Ltd, 2021 3(2021), 1 (DE-627)1760793973 26313316 nnns volume:3 year:2021 number:1 https://doi.org/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/article/9835a389e95741e3beb1953ecb05312e kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2021 1
allfieldsSound	10.4155/fdd-2020-0030 doi (DE-627)DOAJ010637346 (DE-599)DOAJ9835a389e95741e3beb1953ecb05312e DE-627 ger DE-627 rakwb eng RS1-441 Melanie Leveridge verfasserin aut Melanie Leveridge on ELRIG and a career in drug discovery 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery. Pharmacy and materia medica In Future Drug Discovery Future Science Ltd, 2021 3(2021), 1 (DE-627)1760793973 26313316 nnns volume:3 year:2021 number:1 https://doi.org/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/article/9835a389e95741e3beb1953ecb05312e kostenfrei https://www.future-science.com/doi/10.4155/fdd-2020-0030 kostenfrei https://doaj.org/toc/2631-3316 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2021 1
language	English
source	In Future Drug Discovery 3(2021), 1 volume:3 year:2021 number:1
sourceStr	In Future Drug Discovery 3(2021), 1 volume:3 year:2021 number:1
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Pharmacy and materia medica
isfreeaccess_bool	true
container_title	Future Drug Discovery
authorswithroles_txt_mv	Melanie Leveridge @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	1760793973
id	DOAJ010637346
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010637346</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502072117.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4155/fdd-2020-0030</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010637346</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9835a389e95741e3beb1953ecb05312e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Melanie Leveridge</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Melanie Leveridge on ELRIG and a career in drug discovery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Future Drug Discovery</subfield><subfield code="d">Future Science Ltd, 2021</subfield><subfield code="g">3(2021), 1</subfield><subfield code="w">(DE-627)1760793973</subfield><subfield code="x">26313316</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4155/fdd-2020-0030</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9835a389e95741e3beb1953ecb05312e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.future-science.com/doi/10.4155/fdd-2020-0030</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2631-3316</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Melanie Leveridge
spellingShingle	Melanie Leveridge misc RS1-441 misc Pharmacy and materia medica Melanie Leveridge on ELRIG and a career in drug discovery
authorStr	Melanie Leveridge
ppnlink_with_tag_str_mv	@@773@@(DE-627)1760793973
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
callnumber-label	RS1-441
illustrated	Not Illustrated
issn	26313316
topic_title	RS1-441 Melanie Leveridge on ELRIG and a career in drug discovery
topic	misc RS1-441 misc Pharmacy and materia medica
topic_unstemmed	misc RS1-441 misc Pharmacy and materia medica
topic_browse	misc RS1-441 misc Pharmacy and materia medica
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Future Drug Discovery
hierarchy_parent_id	1760793973
hierarchy_top_title	Future Drug Discovery
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1760793973
title	Melanie Leveridge on ELRIG and a career in drug discovery
ctrlnum	(DE-627)DOAJ010637346 (DE-599)DOAJ9835a389e95741e3beb1953ecb05312e
title_full	Melanie Leveridge on ELRIG and a career in drug discovery
author_sort	Melanie Leveridge
journal	Future Drug Discovery
journalStr	Future Drug Discovery
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
author_browse	Melanie Leveridge
container_volume	3
class	RS1-441
format_se	Elektronische Aufsätze
author-letter	Melanie Leveridge
doi_str_mv	10.4155/fdd-2020-0030
title_sort	melanie leveridge on elrig and a career in drug discovery
callnumber	RS1-441
title_auth	Melanie Leveridge on ELRIG and a career in drug discovery
abstract	Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery.
abstractGer	Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery.
abstract_unstemmed	Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Melanie Leveridge on ELRIG and a career in drug discovery
url	https://doi.org/10.4155/fdd-2020-0030 https://doaj.org/article/9835a389e95741e3beb1953ecb05312e https://www.future-science.com/doi/10.4155/fdd-2020-0030 https://doaj.org/toc/2631-3316
remote_bool	true
ppnlink	1760793973
callnumber-subject	RS - Pharmacy
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.4155/fdd-2020-0030
callnumber-a	RS1-441
up_date	2024-07-03T15:55:52.570Z
_version_	1803573948657434624
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ010637346</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502072117.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230225s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.4155/fdd-2020-0030</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ010637346</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ9835a389e95741e3beb1953ecb05312e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Melanie Leveridge</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Melanie Leveridge on ELRIG and a career in drug discovery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Melanie Leveridge is a Senior Director at GSK, a science-led global healthcare company headquartered in Brentford, UK. She has recently been elected Chair of ELRIG (York, UK), the European Laboratory Research and Innovation Group. Here she speaks to Future Drug Discovery Editor Jennifer Straiton about what she hopes to achieve during her tenure as ELRIG Chair and gives her advice for Early Career Researchers just starting out in the field of drug discovery.</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Future Drug Discovery</subfield><subfield code="d">Future Science Ltd, 2021</subfield><subfield code="g">3(2021), 1</subfield><subfield code="w">(DE-627)1760793973</subfield><subfield code="x">26313316</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.4155/fdd-2020-0030</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/9835a389e95741e3beb1953ecb05312e</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.future-science.com/doi/10.4155/fdd-2020-0030</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2631-3316</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield></datafield></record></collection>
score	7.400199

Nicht das Richtige dabei?

Schreiben Sie uns!

Melanie Leveridge on ELRIG and a career in drug discovery

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?